PF06840003 是口服具有活力的、选择性的IDO-1抑制剂，抑制 hIDO-1， dIDO-1和 mIDO-1 的IC50分别为 0.41 μM， 0.59 μM，和 1.5 μM。

PF-06840003 is a specific and oral active IDO-1 inhibitor.

The s of PF-06840003 has inhibitory for hIDO-1 (IC50: 0.41 μM), mouse IDO-1 (IC50: 1.5 μM) and dog IDO-1 (IC50: 0.59 μM), respectively. It has very weak inhibitory against hTDO-2 (IC50: 140 μM). In cellular assays, PF-06840003 shows activity both in the LPS/INFγ-stimulated THP1 cells (IC50: 1.7 μM) and in the HeLa assay (IC50: 1.8 μM). PF-06840003 is a very weak inhibitory against CYPs (IC50>100 μM) except 2C19 (IC50: 78 μM).

In mice, PF-06840003 reduces intratumoral kynurenine levels (>80%). In multiple preClinicalal syngeneic models in mice, It inhibits tumor growth by combinated with immune checkpoint inhibitors. PF-0684003 has favorable predicted human pharmacokinetic properties, including a predicted t1/2 of 16-19 hours.

198474-05-4

C12H9FN2O2

232.21

EOS200271;PF 06840003

DMSO:28 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years